Quality by Design (QbD)

Quality by Design (QbD)

Framework for tablet manufacturing, covering Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), their relationship, and a practical risk assessment.

1. Tablet Manufacturing – Critical Quality Attributes (CQAs)

CQAs are physical, chemical, microbiological, or performance characteristics that must remain within an appropriate limit/range to ensure the finished tablet meets its intended quality and performance.

No. CQA Typical Acceptance Criteria* Why Critical
1 Appearance Conforms to approved specification Detects defects, contamination, and visual nonconformity
2 Identification Conforms Confirms correct API
3 Assay Approved specification Ensures correct potency
4 Content Uniformity / Uniformity of Dosage Units Pharmacopoeial requirement Ensures dose consistency
5 Weight Variation Approved IPC/specification Controls dose and process consistency
6 Hardness / Crushing Strength Product-specific Affects mechanical integrity and disintegration
7 Friability Typically NMT 1.0% where applicable Indicates resistance to abrasion
8 Disintegration Time Product-specific/pharmacopoeial Influences drug release
9 Dissolution Product-specific specification Critical for drug release and bioavailability
10 Moisture / LOD Product-specific Can affect stability, compression, and dissolution
11 Thickness Product-specific Indicates dimensional consistency
12 Related Substances / Degradation Products Approved specification Controls chemical purity and stability
13 Microbial Quality Pharmacopoeial/product requirement Controls microbiological quality
14 Residual Solvents Approved specification, where applicable Safety and product quality
15 Coating attributes, if applicable Appearance, weight gain, defects, etc. Ensures protection, identification or modified release

*Acceptance criteria must be established from the approved product specification, pharmacopoeia, development studies and regulatory requirements.

2. Critical Process Parameters (CPPs)

A CPP is a process parameter whose variability can have an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality.

A. Dispensing and Material Handling

Process Parameter Potential Impact on CQA Criticality
Material identity Assay, identification, CU High
Material quantity/weighing accuracy Assay, weight variation, CU High
Sieve size Blend uniformity, flow, dissolution Medium
Sifting time Particle characteristics Medium
Material storage temperature/RH Moisture, stability Medium/High
Material hold time Moisture, assay, microbial quality Medium

B. Granulation – Wet Granulation

CPP Potential CQA Impact
Impeller speed Granule size, density, flow
Chopper speed Granule size distribution
Binder concentration Granule strength, dissolution
Binder addition rate Granule properties
Binder quantity Granule strength/disintegration
Granulation time Granule size/density
End-point determination Moisture, granule properties
Wet massing time Granule characteristics
Wet granule temperature Moisture/stability

C. Fluid Bed Drying

CPP Potential CQA Impact
Inlet air temperature Moisture, degradation
Product temperature Stability/moisture
Airflow Drying uniformity
Drying time Moisture/LOD
Outlet air temperature Drying endpoint
Final LOD Compression, stability, dissolution
Filter condition Drying efficiency/contamination control

D. Milling

CPP Potential CQA Impact
Mill speed Particle-size distribution
Screen size Granule particle size
Feed rate Milling efficiency
Mill type Particle morphology
Milling time Particle-size distribution

E. Blending/Lubrication

CPP Potential CQA Impact
Blender speed Blend uniformity
Blending time Content uniformity
Lubrication time Dissolution, hardness
Lubricant concentration Dissolution, tablet strength
Order of addition Blend uniformity
Blender load Mixing efficiency
Material flow characteristics Blend uniformity

Over-lubrication is particularly important because excessive lubricant exposure can reduce tablet hardness and slow disintegration/dissolution.

F. Compression

CPP Potential CQA Impact
Pre-compression force Hardness, thickness
Main compression force Hardness, friability, dissolution
Turret speed Weight variation, compression
Feeder speed Weight variation, CU
Fill depth Tablet weight
Compression dwell time Hardness, CU
Ejection force Capping, sticking
Tablet press temperature Product stability
Punch/die condition Appearance, defects
Dedusting efficiency Appearance/contamination

G. Film Coating

CPP Potential CQA Impact
Pan speed Coating uniformity
Spray rate Coating defects
Atomization pressure Droplet size/coating quality
Inlet air temperature Drying/coating defects
Product temperature Coating quality
Airflow Drying efficiency
Spray gun-to-bed distance Coating uniformity
Coating suspension solids Weight gain/coating thickness
Coating weight gain Appearance, dissolution
Spray pattern Uniformity
Exhaust temperature Drying control

3. Risk Assessment – FMEA Approach

A practical pharmaceutical risk assessment can use:

Severity (S): 1–5 , Occurrence (O): 1–5 , Detectability (D): 1–5

RPN = S × O × D

Score Risk Level
1–20 Low
21–40 Medium
41–75 High
76–125 Very High

The exact risk bands should be defined in your site’s approved Quality Risk Management SOP.


4. Tablet Manufacturing CPP–CQA Risk Assessment

Process Step CPP / Parameter Potential Failure Mode Impact on CQA S O D RPN Risk
Dispensing Weighing accuracy Incorrect quantity Assay/CU 5 2 2 20 Low
Sifting Screen size Incorrect PSD Flow/CU/dissolution 4 3 3 36 Medium
Granulation Binder quantity Excess/insufficient binder Hardness/disintegration/dissolution 5 3 3 45 High
Granulation Granulation time Under/over granulation PSD, hardness, dissolution 5 3 3 45 High
Granulation Impeller speed Incorrect granule formation PSD/flow/compression 4 3 3 36 Medium
FBD Inlet temperature Excessive/insufficient drying Moisture/degradation 5 3 3 45 High
FBD Drying time Improper LOD Stability/compression/dissolution 5 3 3 45 High
Milling Screen size Incorrect granule size Flow/CU/compression 4 3 3 36 Medium
Blending Blending time Under/over blending CU/dissolution 5 3 4 60 High
Lubrication Lubrication time Over-lubrication Dissolution/hardness 5 3 4 60 High
Lubrication Lubricant quantity Excess lubricant Dissolution/hardness 5 3 3 45 High
Compression Fill depth Incorrect tablet weight Weight variation/assay 5 3 2 30 Medium
Compression Main compression force Excessive force Hardness/disintegration/dissolution 5 3 3 45 High
Compression Turret speed Excessive speed Weight variation/CU/hardness 4 3 3 36 Medium
Compression Feeder speed Poor die filling Weight variation/CU 5 3 3 45 High
Compression Ejection force Excessive force Capping/sticking/appearance 4 3 3 36 Medium
Compression Punch/die condition Damaged tooling Appearance/weight/hardness 4 3 2 24 Medium
Coating Spray rate Excessive spray Picking/sticking/coating defects 4 3 3 36 Medium
Coating Inlet air temperature Improper drying Coating defects/degradation 5 3 3 45 High
Coating Pan speed Poor coating distribution Uniformity/appearance 4 3 3 36 Medium
Coating Atomization pressure Incorrect droplet size Coating uniformity/appearance 4 3 3 36 Medium
Coating Weight gain Incorrect coating Appearance/dissolution 5 3 3 45 High

5. CPP–CQA Relationship Matrix

A useful approach for pharmaceutical process validation is to establish which CPPs have a direct relationship with CQAs.

H = High impact, M = Medium impact, and L = Low impact

CPP Assay CU Weight Hardness Friability DT Dissolution Moisture
Weighing accuracy H H M L L L L L
Sieve size L M M M M M M L
Binder quantity L M L H H H H M
Granulation time L M L H H H H M
FBD temperature M L L M M M M H
Final LOD M M L H H H H H
Milling screen L M M M M M M L
Blending time L H L L L M M L
Lubrication time L M L H H H H L
Compression force L M L H H H H L
Fill depth L M H M M M M L
Feeder speed L H H M M M M L
Turret speed L M H M M M M L
Coating spray rate L L L L L M H M
Coating weight gain L L L L L M H L

6. Recommended Control Strategy

For a  tablet product, the control strategy should generally include:

Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)